The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease Among Patients With High-Risk Hydatidiform Mole
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 99
- 试验地点
- 1
- 主要终点
- Elevated HCG Level
研究概览
简要总结
A randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform mole.
详细描述
A randomized, controlled trial to evaluate the efficacy of methotrexate for the prevention of postmolar gestational trophoblastic disease among patients with high-risk hydatidiform mole.
Women who will undergo suction curettage for complete hydatidiform mole at the Philippine General Hospital, who are at risk for developing postmolar gestational trophoblastic disease will be included in the study. Patients will receive either a single course of methotrexate or vitamin B complex (Benutrex) within fourteen days from molar evacuation. Patients' serum beta HCG will be monitored 1 week after molar evacuation and then every 2 weeks until the titers become normal for three consecutive determinations, then monthly for 6 months (every 2 months for the next 6 months).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 年龄范围
- 35 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •diagnosis and molar evacuation done at the Department of Obstetrics and Gynecology of the Philippine General Hospital;
- •patients who will undergo suction curettage for evacuation of molar pregnancy;
- •histopathologically confirmed complete hydatidiform mole;
- •must have at least one of the following risk factors for the development of postmolar gestational trophoblastic disease:
- •uterine size larger than age of gestation of more than 6 weeks
- •serum B-hCG titer more than or equal to 100,000 mlU/ml
- •theca lutein cysts more than or equal to 6 cms in size
- •gravidity of 4 or more
- •recurrent molar pregnancy
- •medical complications arising from trophoblastic proliferation such as DIC, pre-eclampsia, thyrotoxicosis, pulmonary insufficiency
- •complete data;
- •patient must have at least one year of regular follow-up and hCG monitoring following onset of remission;
- •should have signed the consent form.
排除标准
- •patients who are lost to follow-up or with incomplete data
- •patients who underwent total hysterectomy for evacuation of molar pregnancy
- •patients who are unable to complete the methotrexate treatment
- •patients who get pregnant within a year following remission
- •patients with a previous history of gestational trophoblastic neoplasia
- •patients with medical problems/complications that inhibit administration of methotrexate
研究组 & 干预措施
Chemoprohylaxis Group
Chemoprohylaxis Group: the treatment group, will be given a single course of methotrexate within fourteen days from molar evacuation. Methotrexate will be given at 0.4 mg/kg intramuscularly per day for 5 days. No chemotherapy will be administered if the hemoglobin is lower than 10 g/L, WBC is less than 3.0 x 10 g/L or more than 10.0 x 10 g/L, absolute neutrophil count is less than 1.5, platelet count is lower than 100,000/cu.cc., patient has elevated liver and renal function test and has concurrent infection.
干预措施: Methotrexate (Drug)
Control Group
Control Group: will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
干预措施: Vitamin B Complex (Drug)
结局指标
主要结局
Elevated HCG Level
时间窗: 4-14 weeks
1. Diagnosis of postmolar gestational trophoblastic diseases will be based on the occurrence of any of the following conditions: * high level of hCG more than 4 weeks post-evacuation (serum level of 20,000mlU/m) * progressively increasing or plateuing hCG values at any time after evacuation (minimum of 3 weekly determinations) * clinical or histologic evidence of metastasis at any site * persistently elevated hCG titer at 14 weeks post-evacuation * elevation of previously normal hCG titer after evacuation provided the diagnosis of pregnancy is excluded 2. Toxicity brought about by the administration of methotrexate will be graded based on the WHO toxicity scoring system.
次要结局
未报告次要终点